Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Yoichiro Nuki, Motohiro Esaki, Kouichi Asano, Yuji Maehata, Junji Umeno, Tomohiko Moriyama, Shotaro Nakamura, Takayuki Matsumoto & Takanari Kitazono. (2016) Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scandinavian Journal of Gastroenterology 51:6, pages 700-705.
Read now
Read now
Luis Fernández-Salazar, Fernando Muñoz, Jesús Barrio, Concepción Muñoz, Ramón Pajares, Montserrat Rivero, Vanessa Prieto, Jesús Legido, Abdel Bouhmidi, Maite Herranz, Nereida Fernández, Ramón Sánchez-Ocaña, Diana Joao & Fernando Santos. (2016) Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study). Scandinavian Journal of Gastroenterology 51:2, pages 186-195.
Read now
Read now
Katrine Risager Christensen, Casper Steenholdt & Jørn Brynskov. (2015) Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study. Scandinavian Journal of Gastroenterology 50:8, pages 1018-1024.
Read now
Read now
Peter Rolny & Morten Vatn. (2013) Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article.. Scandinavian Journal of Gastroenterology 48:2, pages 131-135.
Read now
Read now
Rolf Hultcrantz. (2010) This month in Scandinavian Journal of Gastroenterology. Scandinavian Journal of Gastroenterology 45:12, pages 1395-1396.
Read now
Read now
Articles from other publishers (18)
Edo H J Savelkoul, Pepijn W A Thomas, Lauranne A A P Derikx, Nathan den Broeder, Tessa E H Römkens & Frank Hoentjen. (2022) Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis. Inflammatory Bowel Diseases.
Crossref
Crossref
C. Fradet, J. Kern, P. Atanasov, D. Wirth & A. Borsi. (2020) Impact of surgery and its complications in ulcerative colitis patients in clinical practice: A systematic literature review of real-world evidence in Europe. International Journal of Surgery Open 22, pages 22-32.
Crossref
Crossref
Francesca Di Candido, Gionata Fiorino, Marco Spadaccini, Silvio Danese & Antonino Spinelli. (2019) Are Surgical Rates Decreasing in the Biological Era In IBD?. Current Drug Targets 20:13, pages 1356-1362.
Crossref
Crossref
Daniel J Wong, Eve M Roth, Joseph D Feuerstein & Vitaliy Y Poylin. (2019) Surgery in the age of biologics. Gastroenterology Report 7:2, pages 77-90.
Crossref
Crossref
L. Angelison, S. Almer, A. Eriksson, P. Karling, U. Fagerberg, J. Halfvarson, M. Thörn, J. Björk, U. Hindorf, R. Löfberg, A. Bajor, H. Hjortswang, P. Hammarlund, O. Grip, J. Torp, J. Marsal & E. Hertervig. (2017) Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients. Alimentary Pharmacology & Therapeutics 45:4, pages 519-532.
Crossref
Crossref
Shailja C. Shah, Jean-Frederic Colombel, Bruce E. Sands & Neeraj Narula. (2016) Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 14:9, pages 1245-1255.e8.
Crossref
Crossref
John G Williams, M Fasihul Alam, Laith Alrubaiy, Clare Clement, David Cohen, Michelle Grey, Mike Hilton, Hayley A Hutchings, Mirella Longo, Jayne M Morgan, Frances L Rapport, Anne C Seagrove & Alan Watkins. (2016) Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). Health Technology Assessment 20:44, pages 1-320.
Crossref
Crossref
Kymberley Thorne, Laith Alrubaiy, Ashley Akbari, David G. Samuel, Sian Morrison-Rees & Stephen E. Roberts. (2016) Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin. European Journal of Gastroenterology & Hepatology 28:4, pages 369-382.
Crossref
Crossref
G. Dumitrescu, A. Amiot, P. Seksik, C. Baudry, C. Stefanescu, C. Gagniere, M. Allez, J. Cosnes & Y. Bouhnik. (2015) The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. Alimentary Pharmacology & Therapeutics 42:10, pages 1192-1199.
Crossref
Crossref
Marina Aloi, Giulia D’Arcangelo, Martina Capponi, Federica Nuti, Francesca Vassallo, Fortunata Civitelli, Salvatore Oliva, Giuseppe Pagliaro & Salvatore Cucchiara. (2015) Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapy. Digestive and Liver Disease 47:6, pages 455-459.
Crossref
Crossref
Bikash Devaraj & Andreas M. Kaiser. (2015) Surgical Management of Ulcerative Colitis in the Era of Biologicals. Inflammatory Bowel Diseases 21:1, pages 208-220.
Crossref
Crossref
Marc Ferrante, Séverine Vermeire, Gert Van Assche & Paul Rutgeerts. 2014. Medical Therapy of Ulcerative Colitis. Medical Therapy of Ulcerative Colitis
175
184
.
M. Sjöberg, A. Magnuson, J. Björk, C. Benoni, S. Almer, I. Friis-Liby, E. Hertervig, M. Olsson, P. Karlén, A. Eriksson, G. Midhagen, M. Carlson, A. Lapidus, J. Halfvarson & C. Tysk. (2013) Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Alimentary Pharmacology & Therapeutics 38:4, pages 377-387.
Crossref
Crossref
A. Croft, A. Walsh, J. Doecke, R. Cooley, M. Howlett & G. Radford-Smith. (2013) Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Alimentary Pharmacology & Therapeutics 38:3, pages 294-302.
Crossref
Crossref
Nicolas Williet, Claire Pillot, Abderrahim Oussalah, Vincent Billioud, Jean-Baptiste Chevaux, Laurent Bresler, Marc-André Bigard, Jean-Louis Gueant & Laurent Peyrin-Biroulet. (2012) Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflammatory Bowel Diseases 18:9, pages 1641-1646.
Crossref
Crossref
Jun Hyung ChoChang Kyun LeeHyo Jong KimJae Jun ShimJae Young JangSeok Ho DongByung Ho KimYoung Woon Chang. (2012) Efficacy of Infliximab Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: Single Center Experience. Intestinal Research 10:2, pages 152.
Crossref
Crossref
Henit Yanai & Stephen B Hanauer. (2011) Assessing Response and Loss of Response to Biological Therapies in IBD. American Journal of Gastroenterology 106:4, pages 685-698.
Crossref
Crossref
T. Molnár, K. Farkas, Z. Szepes, F. Nagy & T. Wittmann. (2011) Infliximab rescue therapy in steroid-refractory ulcerative colitis: is more really more?. Alimentary Pharmacology & Therapeutics 33:3, pages 412-413.
Crossref
Crossref